Onintza Sagredo

3.1k total citations
37 papers, 2.2k citations indexed

About

Onintza Sagredo is a scholar working on Cellular and Molecular Neuroscience, Pharmacology and Psychiatry and Mental health. According to data from OpenAlex, Onintza Sagredo has authored 37 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Cellular and Molecular Neuroscience, 29 papers in Pharmacology and 6 papers in Psychiatry and Mental health. Recurrent topics in Onintza Sagredo's work include Cannabis and Cannabinoid Research (29 papers), Neuroscience and Neuropharmacology Research (25 papers) and Genetic Neurodegenerative Diseases (11 papers). Onintza Sagredo is often cited by papers focused on Cannabis and Cannabinoid Research (29 papers), Neuroscience and Neuropharmacology Research (25 papers) and Genetic Neurodegenerative Diseases (11 papers). Onintza Sagredo collaborates with scholars based in Spain, Italy and United Kingdom. Onintza Sagredo's co-authors include Javier Fernández‐Ruíz, M. Ruth Pazos, Raphael Mechoulam, J.A. Ramos, Sara Valdeolivas, Roger G. Pertwee, Manuel Guzmán, Concepción García, Ismael Galve‐Roperh and Julián Romero and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Brain.

In The Last Decade

Onintza Sagredo

35 papers receiving 2.1k citations

Peers

Countries citing papers authored by Onintza Sagredo

Since Specialization

Citations

This map shows the geographic impact of Onintza Sagredo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Onintza Sagredo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Onintza Sagredo more than expected).

Fields of papers citing papers by Onintza Sagredo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Onintza Sagredo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Onintza Sagredo. The network helps show where Onintza Sagredo may publish in the future.

Co-authorship network of co-authors of Onintza Sagredo

This figure shows the co-authorship network connecting the top 25 collaborators of Onintza Sagredo. A scholar is included among the top collaborators of Onintza Sagredo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Onintza Sagredo. Onintza Sagredo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ageing, Neurodegeneration and the Endocannabinoid System 2025 ·Current topics in behavioral neurosciences ·Javier Fernández‐Ruíz, Onintza Sagredo, María Gómez‐Ruíz, Eva de Lago	0
2	Investigation in blood-brain barrier integrity and susceptibility to immune cell penetration in a mouse model of Dravet syndrome 2025 ·Brain Behavior & Immunity - Health ·(unknown), Alicia García‐Culebras, Valentina Satta, (unknown), (unknown), (unknown), Ignacio Lizasoaín, Javier Fernández‐Ruíz, Onintza Sagredo	2
3	Retinal Tissue Shows Glial Changes in a Dravet Syndrome Knock-in Mouse Model 2023 ·International Journal of Molecular Sciences ·Juan J. Salazar, (unknown), (unknown), José A. Fernández‐Albarral, Elena Salobrar‐García, Inés López‐Cuenca, Rosa de Hoz, (unknown), José M. Ramı́rez, (unknown), Valentina Satta, (unknown), Onintza Sagredo, Ana I. Ramı́rez	3
4	Neuropathological Characterization of a Dravet Syndrome Knock-In Mouse Model Useful for Investigating Cannabinoid Treatments 2021 ·Frontiers in Molecular Neuroscience ·Valentina Satta, (unknown), Paula Díez, Soraya Martín‐Suárez, (unknown), Juan Manuel Encinas, Javier Fernández‐Ruíz, Onintza Sagredo	19
5	Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome 2021 ·Neuropharmacology ·(unknown), Valentina Satta, (unknown), Javier Fernández‐Ruíz, Onintza Sagredo	10
6	Possible therapeutic applications of cannabis in the neuropsychopharmacology field 2020 ·European Neuropsychopharmacology ·Javier Fernández‐Ruíz, Ismael Galve‐Roperh, Onintza Sagredo, Manuel Guzmán	24
7	Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders 2018 ·Biochemical Pharmacology ·Onintza Sagredo, Javier Palazuelos, Ana Gutiérrez‐Rodrίguez, Valentina Satta, Ismael Galve‐Roperh, José Martínez‐Orgado	17
8	Tratamiento microquirúrgico de la neuralgia trigeminal en mayores de 70 años, estudio de eficacia y seguridad 2016 ·Neurología ·Fernando Ruiz‐Juretschke, (unknown), (unknown), Onintza Sagredo, (unknown), C. Fernández-Carballal	15
9	A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease 2016 ·Journal of Neurology ·José Luis López-Sendón, Juan García Caldentey, Patricia Trigo Cubillo, (unknown), Guillermo García Ribas, Marilyn Arias, María Jesús García de Yébenes, Rosa M. Tolón, Ismael Galve‐Roperh, Onintza Sagredo, Sara Valdeolivas, Eva Resel, Silvia Ortega‐Gutiérrez, Laura García‐Bermejo, Javier Fernández‐Ruíz, Manuel Guzmán, (unknown)	110
10	Neuroprotective Properties of Cannabigerol in Huntington's Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice 2014 ·Neurotherapeutics ·Sara Valdeolivas, Carmen Navarrete, Irene Cantarero, María L. Bellido, Eduardo Muñóz, Onintza Sagredo	111
11	Natural Cannabinoids Improve Dopamine Neurotransmission and Tau and Amyloid Pathology in a Mouse Model of Tauopathy 2013 ·Journal of Alzheimer s Disease ·Marı́a José Casarejos, Juan Perucho, Ana Gómez, María Paz Muñoz, Marian Fernandez-Estévez, Onintza Sagredo, Javier Fernández‐Ruíz, Manuel Guzmán, Justo Garcı́a de Yébenes, María A. Mena	99
12	The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG 2013 ·Cell Death and Disease ·Sara Valdeolivas, M. Ruth Pazos, Tiziana Bisogno, Fabiana Piscitelli, Fabio Arturo Iannotti, Marco Allarà, Onintza Sagredo, Vincenzo Di Marzo, Javier Fernández‐Ruíz	69
13	Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington’s Disease: Role of CB₁ and CB₂ Receptors 2012 ·ACS Chemical Neuroscience ·Sara Valdeolivas, Valentina Satta, Roger G. Pertwee, Javier Fernández‐Ruíz, Onintza Sagredo	75
14	Cannabinoids: Novel Medicines for the Treatment of Huntingtons Disease 2011 ·PubMed ·Onintza Sagredo, M. Ruth Pazos, Sara Valdeolivas, Javier Fernández‐Ruíz	58
15	Lack of association between polymorphisms in cannabinoid receptor gene (CNR1) and fatty acid amide hydroxylase gene (FAAH) and eating disorders in a preliminary study 2009 ·Psychiatric Genetics ·F. Árias, Israel Ampuero, Onintza Sagredo, (unknown), Sergio Sánchez, (unknown), J.A. Ramos	5
16	Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity 2009 ·Brain ·Javier Palazuelos, Tania Aguado, M. Ruth Pazos, Boris Julien, Carolina Carrasco, Eva Resel, Onintza Sagredo, Cristina Benito, Julián Romero, Íñigo Azcoitia, Javier Fernández‐Ruíz, Manuel Guzmán, Ismael Galve‐Roperh	311
17	Cannabidiol reduced the striatal atrophy caused 3‐nitropropionic acidin vivoby mechanisms independent of the activation of cannabinoid, vanilloid TRPV₁and adenosine A_2Areceptors 2007 ·European Journal of Neuroscience ·Onintza Sagredo, J.A. Ramos, Alessandra Decio, Raphael Mechoulam, Javier Fernández‐Ruíz	124
18	Cannabinoids and Neuroprotection in Basal Ganglia Disorders 2007 ·Molecular Neurobiology ·Onintza Sagredo, Moisés Garcı́a-Arencibia, Eva de Lago, (unknown), Alessandra Decio, Javier Fernández‐Ruíz	74
19	Therapeutic Potential of the Endocannabinoid System in the Brain 2005 ·Mini-Reviews in Medicinal Chemistry ·José Geraldo Lopes Ramos, Sara González, Onintza Sagredo, María Gómez‐Ruíz, Javier Fernández‐Ruíz	12
20	Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats 2002 ·Developmental Brain Research ·Eva Romero, Beatriz Martín‐Fernández, Onintza Sagredo, Núria Gómez, Leyre Urigüen, Carmen Guaza, Rosario de Miguel, J.A. Ramos, María‐Paz Viveros	73

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact